Schmitz, E M H <br/><br/>
Therapeutic drug monitoring (TDM) as a tool in the switch from infliximab innovator to biosimilar in rheumatic patients: results of a 12-month observational prospective cohort study.  [electronic resource] 

 -  Clinical rheumatology  Sep 2017 
 - 2129-2134 p.  digital 
<br/><br/> Publication Type: Journal Article; Observational Study 
<br/><br/><label>ISSN: </label>1434-9949 
<br/><br/><label>Standard No.: </label>10.1007/s10067-017-3686-6  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Antirheumatic Agents--administration & dosage<br/>Biosimilar Pharmaceuticals--administration & dosage<br/>C-Reactive Protein--analysis<br/>Drug Monitoring<br/>Drug Substitution<br/>Female<br/>Humans<br/>Infliximab--administration & dosage<br/>Male<br/>Middle Aged<br/>Netherlands<br/>Prospective Studies<br/>Rheumatic Diseases--drug therapy<br/>Severity of Illness Index<br/>Treatment Outcome